Is Restylane Contour FDA approved for temples?

Yes, Galderma recently secured FDA approval for Restylane Contour for temple hollowing and age-related volume loss in the temporal region. This is a new indication that expands Restylane's structural filler portfolio beyond previous approved uses.

Why is temple filler treatment considered high-skill?

Temple injections require anatomically precise, three-dimensional placement because improper needle placement risks vascular compromise and blindness. This high-risk profile means the procedure attracts experienced injectors who can command premium per-syringe fees.

What's the margin difference between temple filler and standard filler treatments?

Temple treatments are positioned as high-margin procedures because practitioners can charge premium per-syringe fees for the specialized anatomical knowledge and skill required. The exact margin varies by practice, but the structural nature and complexity justify higher pricing than standard facial filler work.

Should I switch to Restylane Contour if I'm currently doing temple fillers off-label?

The FDA approval gives you a branded, cleared option for a procedure many practices already perform off-label with other HA fillers. If you're already in Restylane's loyalty or rebate program, adding this indication is an easy upsell; if you're weighted toward AbbVie products, this may create competitive pressure on your per-unit acquisition costs.

How does the Restylane temple approval affect pricing strategy?

The approval sits within Galderma's loyalty and rebate infrastructure, likely tied to Restylane's broader bundling strategy. Practices already committed to Restylane may see bundled pricing incentives, while this new indication could shift per-unit costs for practices considering a switch from competitors.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

Galderma Wins FDA Approval for Restylane Contour — Temple Indication Expands Structural Filler Segment

New indication for temple volume restoration adds a high-skill, high-margin treatment to Restylane's portfolio.

By Evan at Inside MedSpa · Jul 2, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Galderma has secured FDA approval for Restylane Contour for temple hollowing, a structural filler indication that targets age-related volume loss in the temporal region. This approval expands Restylane's footprint in the premium contouring space, where practitioners command higher per-syringe fees for anatomically precise, three-dimensional work.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/restylane-contour-fda-temple-hollowing-approval/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Galderma Wins FDA Approval for Restylane Contour — Temple Indication Expands Structural Filler Segment

Share

Discussion

Leave a comment

By the time it's news, it's too late.